Anti Epilepsy Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
Epilepsy is a disorder of central nervous system which fall in class of neurological disorders. Epilepsy is an abnormal state of brain activity which leads to seizures, convulsions, loss of sensations, repeated attacks of seizures. Epilepsy is seen in both male and female. Drug therapy and sometime surgery can help to correct epilepsy but some patients require lifelong treatment to control seizures. The symptoms of epilepsy are, confusion, loss of sensation and awareness, anxiety and convulsions. Several drug therapies are available to treat such a condition such as first, second and third generation antiepileptic drugs.
MARKET DYNAMICS
The key market drivers for Anti Epilepsy Drugs Market Includes, rising prevalence of neurological disorders such as, epilepsy, anxiety, bipolar disorders. Additionally, government initiatives to organize different awareness programs regarding epilepsy and also various initiatives for making treatment facilities available is also expected to fuel market growth during forecast period. Moreover, development of novel drug therapies by pharmaceutical R&D is also expected to boost the market growth. However, lack of proper supply chain for epilepsy drugs along with side effects associated with treatment expected to restrain market growth during forecast period.
MARKET SCOPE
The "Anti Epilepsy Drugs Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Anti-Epilepsy Drugs market with detailed market segmentation by treatment and channel of distribution. The Anti-Epilepsy Drugs Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Anti Epilepsy Drugs Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Anti Epilepsy Drugs Market is segmented on the basis of treatment and channel of distribution. On the basis of treatment the market is segmented as, first generation anti-epileptics, second generation anti- epileptics, third generation anti- epileptics. And on the basis of channel of distribution the market is segmented as, hospital pharmacies, retail pharmacies and other.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Anti-Epilepsy Drugs Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Anti- Epilepsy Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Anti Epilepsy Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Anti- Epilepsy Drugs Market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Anti-Epilepsy Drugs Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Anti- Epilepsy Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Anti Epilepsy Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Anti- Epilepsy Drugs Market in these regions.
MARKET PLAYERS
The report covers key developments in the Anti Epilepsy Drugs Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Anti Epilepsy Drugs Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, Anti Epilepsy Drugs market in the global market. Below mentioned is the list of few companies engaged in the Anti Epilepsy Drugs Market.
The report also includes the profiles of key players in Anti Epilepsy Drugs Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- GlaxoSmithKline Plc.
- UCB Pharma Ltd
- Sanofi S.A
- Valeant Pharmaceuticals
- Johnson and Johnson
- Novartis AG
- Pfizer Inc.
- Sunovion Pharmaceuticals, Inc.
- Eisai Co., Ltd
- Abbott Laboratories
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti Epilepsy Drugs Market - By Treatment
1.3.2 Anti Epilepsy Drugs Market - By Channel of Distribution
1.3.3 Anti Epilepsy Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI EPILEPSY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. ANTI EPILEPSY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI EPILEPSY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI EPILEPSY DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI EPILEPSY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI EPILEPSY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
7.1. OVERVIEW
7.2. TREATMENT MARKET FORECASTS AND ANALYSIS
7.3. FIRST GENERATION ANTI-EPILEPTICS
7.3.1. Overview
7.3.2. First Generation Anti-epileptics Market Forecast and Analysis
7.4. SECOND GENERATION ANTI-EPILEPTICS
7.4.1. Overview
7.4.2. Second Generation Anti-epileptics Market Forecast and Analysis
7.5. THIRD GENERATION ANTI-EPILEPTICS
7.5.1. Overview
7.5.2. Third Generation Anti-epileptics Market Forecast and Analysis
8. ANTI EPILEPSY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - CHANNEL OF DISTRIBUTION
8.1. OVERVIEW
8.2. CHANNEL OF DISTRIBUTION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ANTI EPILEPSY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti Epilepsy Drugs Market Overview
9.1.2 North America Anti Epilepsy Drugs Market Forecasts and Analysis
9.1.3 North America Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.1.4 North America Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.1.5 North America Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Anti Epilepsy Drugs Market
9.1.5.1.1 United States Anti Epilepsy Drugs Market by Treatment
9.1.5.1.2 United States Anti Epilepsy Drugs Market by Channel of Distribution
9.1.5.2 Canada Anti Epilepsy Drugs Market
9.1.5.2.1 Canada Anti Epilepsy Drugs Market by Treatment
9.1.5.2.2 Canada Anti Epilepsy Drugs Market by Channel of Distribution
9.1.5.3 Mexico Anti Epilepsy Drugs Market
9.1.5.3.1 Mexico Anti Epilepsy Drugs Market by Treatment
9.1.5.3.2 Mexico Anti Epilepsy Drugs Market by Channel of Distribution
9.2. EUROPE
9.2.1 Europe Anti Epilepsy Drugs Market Overview
9.2.2 Europe Anti Epilepsy Drugs Market Forecasts and Analysis
9.2.3 Europe Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.2.4 Europe Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.2.5 Europe Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti Epilepsy Drugs Market
9.2.5.1.1 Germany Anti Epilepsy Drugs Market by Treatment
9.2.5.1.2 Germany Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.2 France Anti Epilepsy Drugs Market
9.2.5.2.1 France Anti Epilepsy Drugs Market by Treatment
9.2.5.2.2 France Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.3 Italy Anti Epilepsy Drugs Market
9.2.5.3.1 Italy Anti Epilepsy Drugs Market by Treatment
9.2.5.3.2 Italy Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.4 Spain Anti Epilepsy Drugs Market
9.2.5.4.1 Spain Anti Epilepsy Drugs Market by Treatment
9.2.5.4.2 Spain Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.5 United Kingdom Anti Epilepsy Drugs Market
9.2.5.5.1 United Kingdom Anti Epilepsy Drugs Market by Treatment
9.2.5.5.2 United Kingdom Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.6 Rest of Europe Anti Epilepsy Drugs Market
9.2.5.6.1 Rest of Europe Anti Epilepsy Drugs Market by Treatment
9.2.5.6.2 Rest of Europe Anti Epilepsy Drugs Market by Channel of Distribution
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti Epilepsy Drugs Market Overview
9.3.2 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.3.4 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.3.5 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Anti Epilepsy Drugs Market
9.3.5.1.1 Australia Anti Epilepsy Drugs Market by Treatment
9.3.5.1.2 Australia Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.2 China Anti Epilepsy Drugs Market
9.3.5.2.1 China Anti Epilepsy Drugs Market by Treatment
9.3.5.2.2 China Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.3 India Anti Epilepsy Drugs Market
9.3.5.3.1 India Anti Epilepsy Drugs Market by Treatment
9.3.5.3.2 India Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.4 Japan Anti Epilepsy Drugs Market
9.3.5.4.1 Japan Anti Epilepsy Drugs Market by Treatment
9.3.5.4.2 Japan Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.5 South Korea Anti Epilepsy Drugs Market
9.3.5.5.1 South Korea Anti Epilepsy Drugs Market by Treatment
9.3.5.5.2 South Korea Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.6 Rest of Asia-Pacific Anti Epilepsy Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Anti Epilepsy Drugs Market by Treatment
9.3.5.6.2 Rest of Asia-Pacific Anti Epilepsy Drugs Market by Channel of Distribution
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti Epilepsy Drugs Market Overview
9.4.2 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.4.4 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.4.5 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti Epilepsy Drugs Market
9.4.5.1.1 South Africa Anti Epilepsy Drugs Market by Treatment
9.4.5.1.2 South Africa Anti Epilepsy Drugs Market by Channel of Distribution
9.4.5.2 Saudi Arabia Anti Epilepsy Drugs Market
9.4.5.2.1 Saudi Arabia Anti Epilepsy Drugs Market by Treatment
9.4.5.2.2 Saudi Arabia Anti Epilepsy Drugs Market by Channel of Distribution
9.4.5.3 Rest of Middle East and Africa Anti Epilepsy Drugs Market
9.4.5.3.1 Rest of Middle East and Africa Anti Epilepsy Drugs Market by Treatment
9.4.5.3.2 Rest of Middle East and Africa Anti Epilepsy Drugs Market by Channel of Distribution
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti Epilepsy Drugs Market Overview
9.5.2 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis
9.5.3 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.5.4 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.5.5 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti Epilepsy Drugs Market
9.5.5.1.1 Brazil Anti Epilepsy Drugs Market by Treatment
9.5.5.1.2 Brazil Anti Epilepsy Drugs Market by Channel of Distribution
9.5.5.2 Argentina Anti Epilepsy Drugs Market
9.5.5.2.1 Argentina Anti Epilepsy Drugs Market by Treatment
9.5.5.2.2 Argentina Anti Epilepsy Drugs Market by Channel of Distribution
9.5.5.3 Rest of South and Central America Anti Epilepsy Drugs Market
9.5.5.3.1 Rest of South and Central America Anti Epilepsy Drugs Market by Treatment
9.5.5.3.2 Rest of South and Central America Anti Epilepsy Drugs Market by Channel of Distribution
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTI EPILEPSY DRUGS MARKET, KEY COMPANY PROFILES
11.1. UCB PHARMA LTD
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SANOFI S.A
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. JOHNSON AND JOHNSON
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. EISAI CO., LTD
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ABBOTT LABORATORIES, INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GLAXOSMITHKLINE PLC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUNOVION PHARMACEUTICALS, INC
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. UCB Pharma Ltd
2. Sanofi S.A
3. Valeant Pharmaceuticals International, Inc.
4. Pfizer, Inc.
5. Johnson and Johnson
6. Eisai Co., Ltd
7. Abbott Laboratories, Inc.
8. Novartis AG
9. GlaxoSmithKline PLC.
10. Sunovion Pharmaceuticals, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For